ELEVATION ONCOLOGY INC (ELEV) Stock Price, Forecast & Analysis
USA - NASDAQ:ELEV - US28623U1016 - Common Stock
ELEV Key Statistics, Chart & Performance
The current stock price of ELEV is 0.365 USD. In the past month the price decreased by -4.85%. In the past year, price decreased by -87.54%.
ELEV Latest News, Press Relases and Analysis
ELEV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.68 | 412.01B | ||
| AMGN | AMGEN INC | 15.38 | 181.04B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.01 | 111.32B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.15 | 72.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 887.73 | 59.35B | ||
| INSM | INSMED INC | N/A | 41.09B | ||
| NTRA | NATERA INC | N/A | 28.75B | ||
| BIIB | BIOGEN INC | 9.65 | 23.67B | ||
| INCY | INCYTE CORP | 16.86 | 21.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.49 | 20.88B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.13 | 14.56B |
Related stock screener links
About ELEV
Company Profile
Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The company is headquartered in Boston, Massachusetts and currently employs 34 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021, is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors. EO-1022 is an ADC containing seribantumab.
Company Info
ELEVATION ONCOLOGY INC
101 Federal Street, Suite 1900
Boston MASSACHUSETTS US
CEO: Shawn Leland
Employees: 29
Phone: 17163711125
ELEVATION ONCOLOGY INC / ELEV FAQ
Can you describe the business of ELEVATION ONCOLOGY INC?
Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The company is headquartered in Boston, Massachusetts and currently employs 34 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021, is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors. EO-1022 is an ADC containing seribantumab.
Can you provide the latest stock price for ELEVATION ONCOLOGY INC?
The current stock price of ELEV is 0.365 USD. The price decreased by -2.12% in the last trading session.
Does ELEV stock pay dividends?
ELEV does not pay a dividend.
How is the ChartMill rating for ELEVATION ONCOLOGY INC?
ELEV has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy ELEV stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ELEV.
ELEV Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ELEV. When comparing the yearly performance of all stocks, ELEV is a bad performer in the overall market: 96.01% of all stocks are doing better.
ELEV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ELEV. While ELEV seems to be doing ok healthwise, there are quite some concerns on its profitability.
ELEV Financial Highlights
Over the last trailing twelve months ELEV reported a non-GAAP Earnings per Share(EPS) of -0.82. The EPS increased by 21.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.36% | ||
| ROE | -102.69% | ||
| Debt/Equity | 0.67 |
ELEV Forecast & Estimates
14 analysts have analysed ELEV and the average price target is 1.52 USD. This implies a price increase of 317.31% is expected in the next year compared to the current price of 0.365.